Myriad Genetics (NASDAQ: MYGN) updates 2025 volumes, 2026 outlook

Rhea-AI Filing Summary

Myriad Genetics, Inc. reported preliminary operating trends for 2025 and introduced financial guidance for full year 2026. In a new press release, the company outlined early revenue figures for the quarter and year ended December 31, 2025 and shared its initial outlook for 2026.

For 2025, Myriad expects total test volumes of approximately 1.5 million, a 1% year-over-year increase. This reflects about 7% growth in hereditary cancer testing and 6% growth in mental health testing, partially offset by roughly a 4% decline in prenatal health testing. All financial figures are described as preliminary and remain subject to normal year-end accounting procedures and external audit, and the company includes standard cautionary language regarding forward-looking statements.

0000899923false00008999232026-01-122026-01-12

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):  January 12, 2026

MYRIAD GENETICS, INC.

(Exact name of registrant as specified in its charter)

Delaware

0-26642

87-0494517

(State or other jurisdiction of incorporation)

(Commission File Number)

(IRS Employer Identification No.)

322 North 2200 West

Salt Lake City, Utah 84116

(Address of principal executive offices) (Zip Code)

Registrant's telephone number, including area code: (801) 584-3600

Not applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐			Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐			Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐			Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐			Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common Stock, $0.01 par value

MYGN

Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

ITEM 2.02    Results of Operations and Financial Condition.

On January 12, 2026, Myriad Genetics, Inc. (the “Company”) issued a press release announcing its preliminary revenue for the quarter and full year ended December 31, 2025. The Company also introduced full year 2026 financial guidance. In addition, the Company is announcing certain preliminary volume information for the full year ended December 31, 2025. Specifically, the Company expects total test volumes in 2025 of approximately 1.5 million, a 1% year-over-year increase, reflecting approximately 7% year-over-year growth in hereditary cancer testing volume, approximately 6% year-over-year growth in mental health testing volume, and approximately 4% year-over-year decrease in prenatal health testing volume. The full text of the press release is furnished as Exhibit 99.1 hereto and incorporated herein by reference.

Cautionary Note Regarding Preliminary Financial Results. The select financial results for the quarter and full year ended December 31, 2025 set forth in this Current Report on Form 8-K, including Exhibit 99.1, are preliminary and subject to the Company’s normal quarter and year-end accounting procedures and external audit by the Company’s independent registered public accounting firm and, as a result, are subject to change. Please refer to the cautionary note in Exhibit 99.1 to this Current Report on Form 8-K regarding these preliminary financial results.

Cautionary Note Regarding Forward-Looking Statements. Except for historical information contained in this Current Report on Form 8-K, including Exhibit 99.1, this Current Report on Form 8-K, including Exhibit 99.1, contains forward-looking statements which involve certain risks and uncertainties that could cause actual results to differ materially from those expressed or implied by these statements. Please refer to the cautionary note in Exhibit 99.1 to this Current Report on Form 8-K regarding these forward-looking statements.

ITEM 9.01    Financial Statements and Exhibits.

Exhibit Number						Description
99.1						Press release of Myriad Genetics, Inc., dated January 12, 2026.
104						Cover Page Interactive Data File (embedded within the Inline XBRL document).

The exhibit(s) may contain hypertext links to information on our website or other parties’ websites. The information on our website and other parties’ websites is not incorporated by reference into this Current Report on Form 8-K and does not constitute a part of this Current Report on Form 8-K.

Limitation on Incorporation by Reference. In accordance with General Instruction B-2 of Form 8-K, the information set forth in Item 2.02 and in Exhibit 99.1 shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

			MYRIAD GENETICS, INC.
Date: January 12, 2026						/s/ Benjamin R. Wheeler
						Benjamin R. Wheeler
						Chief Financial Officer

FAQ

What did Myriad Genetics (MYGN) disclose in this 8-K filing?

Myriad Genetics disclosed that it issued a press release with preliminary revenue for the quarter and full year ended December 31, 2025, introduced full year 2026 financial guidance, and provided selected test volume metrics for 2025.

How many diagnostic tests did Myriad Genetics expect to run in 2025?

The company expects total test volumes of approximately 1.5 million for full year 2025, representing a 1% year-over-year increase.

How did Myriad Genetics’ main testing categories perform in 2025?

For 2025, Myriad Genetics expects about 7% year-over-year growth in hereditary cancer testing volume, about 6% growth in mental health testing volume, and roughly a 4% year-over-year decrease in prenatal health testing volume.

Did Myriad Genetics provide financial guidance for 2026?

Yes. The company stated that it introduced full year 2026 financial guidance in its press release furnished as Exhibit 99.1.

Are the 2025 financial and volume figures from Myriad Genetics final?

No. The company described these as preliminary financial results that are subject to its normal quarter and year-end accounting procedures and external audit, and therefore may change.

Where can investors find more detail on Myriad Genetics’ preliminary 2025 results?

Additional details are contained in the press release furnished as Exhibit 99.1 to the 8-K, which is incorporated by reference into the disclosure, though not deemed "filed" for certain liability purposes.

Does this Myriad Genetics filing include forward-looking statements?

Yes. The company notes that, aside from historical information, the disclosure and Exhibit 99.1 contain forward-looking statements and includes a cautionary note referencing risks and uncertainties that could cause actual results to differ materially.